David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Determining whether US companies and some of the persons involved in them are acting ethically when conducting the research described in the Havrix Case and the Surfaxin Trial requires reflection on the moral objections that could be raised against what they did. Given the wide range of possible moral objections, it would be folly to try to display and discuss them all in the space of this essay. I concentrate then on a kind of moral objections that strike me as especially interesting, plausible, and important. I try to work out whether such objections are valid and, if so, what significance they have for the conduct of the pharmaceutical companies in question — and for the conduct of ourselves as citizens of democratic countries under whose jurisdiction these companies operate.
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library||
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Andrew Cullison (2010). Moral Perception. European Journal of Philosophy 18 (2):159-175.
Mathias Risse (2005). What We Owe to the Global Poor. Journal of Ethics 9 (1-2):81 - 117.
J. Sonderholm (2010). A Reform Proposal in Need of Reform: A Critique of Thomas Pogge's Proposal for How to Incentivize Research and Development of Essential Drugs. Public Health Ethics 3 (2):167-177.
Thomas R. Grimes (1990). Truth, Content, and the Hypothetico-Deductive Method. Philosophy of Science 57 (3):514-522.
Richard T. de George (2005). Intellectual Property and Pharmaceutical Drugs. Business Ethics Quarterly 15 (4):549-575.
Pepe Lee Chang (2006). Who's in the Business of Saving Lives? Journal of Medicine and Philosophy 31 (5):465 – 482.
Thomas W. Pogge (2007). "Assisting" the Global Poor. The Proceedings of the Twenty-First World Congress of Philosophy 13:189-215.
David Barnard (2002). In the High Court of South Africa, Case No. 4138/98: The Global Politics of Access to Low-Cost AIDS Drugs in Poor Countries. [REVIEW] Kennedy Institute of Ethics Journal 12 (2):159-174.
Nicole Hassoun (2012). Global Health Impact: A Basis for Labeling and Licensing Campaigns? Developing World Bioethics 12 (3):121-134.
Added to index2009-01-28
Total downloads108 ( #12,562 of 1,410,046 )
Recent downloads (6 months)6 ( #38,341 of 1,410,046 )
How can I increase my downloads?